Treace Medical Concepts(TMCI)
$4.35-0.18 (-3.97%)
TMCI
Treace Medical Concepts financials statements
$4.35
At close:-0.18 (-3.97%)
Want to see TMCI full AI Analyst Report?
Treace Medical Concepts (TMCI) Ratios
127 Followers
Treace Medical Concepts Ratios
TMCI's free cash flow for Q3 2026 was $-5.43M. For the 2026 fiscal year, TMCI's free cash flow was decreased by $-2.17M and operating cash flow was $-3.25M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.31 | 4.62 | 4.40 | 4.41 | 7.58 |
| Quick Ratio | 3.13 | 3.50 | 3.76 | 3.77 | 7.00 |
| Cash Ratio | 0.35 | 0.32 | 0.29 | 0.64 | 5.81 |
| Solvency Ratio | -0.47 | -0.45 | -0.39 | -0.41 | -0.42 |
| Operating Cash Flow Ratio | -0.52 | -1.06 | -0.77 | -1.01 | -0.94 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 28.80M | $ 57.20M | $ 84.39M | $ 34.91M | $ 90.22M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.07 | 0.32 | 0.28 | 0.43 | 0.21 |
| Debt-to-Equity Ratio | 0.16 | 0.62 | 0.51 | 1.13 | 0.32 |
| Debt-to-Capital Ratio | 0.14 | 0.38 | 0.34 | 0.53 | 0.24 |
| Long-Term Debt-to-Capital Ratio | 0.14 | 0.32 | 0.28 | 0.47 | 0.24 |
| Financial Leverage Ratio | 2.18 | 1.92 | 1.83 | 2.63 | 1.51 |
| Debt Service Coverage Ratio | -8.12 | -8.00 | -7.55 | -8.25 | -3.89 |
| Interest Coverage Ratio | -10.18 | -10.60 | -9.95 | -7.92 | -4.07 |
| Debt to Market Cap | 0.09 | 0.12 | 0.07 | 0.04 | 0.03 |
| Interest Debt Per Share | 0.31 | 1.21 | 1.24 | 1.32 | 0.62 |
| Net Debt to EBITDA | -0.08 | -1.39 | -1.47 | -1.35 | 4.84 |
| Profitability Margins | |||||
| Gross Profit Margin | 79.81% | 80.37% | 81.20% | 80.60% | 82.11% |
| EBIT Margin | -25.24% | -24.12% | -23.71% | -27.09% | -17.47% |
| EBITDA Margin | -20.30% | -20.09% | -20.85% | -25.58% | -16.74% |
| Operating Profit Margin | -25.46% | -26.60% | -27.48% | -24.57% | -17.49% |
| Pretax Profit Margin | -27.74% | -26.63% | -26.47% | -30.19% | -21.77% |
| Net Profit Margin | -27.74% | -26.63% | -26.47% | -30.19% | -21.77% |
| Continuous Operations Profit Margin | -27.74% | -26.63% | -26.47% | -30.19% | -21.77% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 108.95% | 100.10% | 96.30% | 122.88% | 124.48% |
| Return on Assets (ROA) | -30.96% | -25.68% | -19.66% | -26.92% | -14.59% |
| Return on Equity (ROE) | -67.56% | -49.38% | -35.91% | -70.73% | -22.08% |
| Return on Capital Employed (ROCE) | -33.86% | -30.57% | -24.86% | -27.06% | -13.47% |
| Return on Invested Capital (ROIC) | -33.86% | -30.50% | -24.69% | -26.99% | -13.47% |
| Return on Tangible Assets | -34.58% | -28.41% | -21.53% | -26.92% | -14.59% |
| Earnings Yield | -38.06% | -12.06% | -6.38% | -3.37% | -2.03% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.05 | 5.13 | 4.92 | 4.86 | 5.09 |
| Payables Turnover | 6.38 | 3.91 | 2.97 | 3.18 | 4.16 |
| Inventory Turnover | 1.19 | 1.05 | 1.20 | 1.42 | 1.60 |
| Fixed Asset Turnover | 5.69 | 6.09 | 5.93 | 5.57 | 33.14 |
| Asset Turnover | 1.12 | 0.96 | 0.74 | 0.89 | 0.67 |
| Working Capital Turnover Ratio | 1.87 | 1.50 | 1.46 | 1.27 | 1.27 |
| Cash Conversion Cycle | 321.45 | 326.35 | 254.87 | 216.53 | 212.37 |
| Days of Sales Outstanding | 72.34 | 71.14 | 74.25 | 75.13 | 71.78 |
| Days of Inventory Outstanding | 306.29 | 348.67 | 303.41 | 256.35 | 228.25 |
| Days of Payables Outstanding | 57.18 | 93.46 | 122.79 | 114.95 | 87.66 |
| Operating Cycle | 378.63 | 419.81 | 377.66 | 331.48 | 300.03 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.25 | -0.60 | -0.57 | -0.55 | -0.32 |
| Free Cash Flow Per Share | -0.47 | -0.79 | -0.76 | -0.82 | -0.37 |
| Dividend Paid and CapEx Coverage Ratio | -1.18 | -3.21 | -3.02 | -2.07 | -6.36 |
| Capital Expenditure Coverage Ratio | -1.18 | -3.21 | -3.02 | -2.07 | -6.36 |
| Operating Cash Flow Coverage Ratio | -1.14 | -0.53 | -0.49 | -0.45 | -0.59 |
| Operating Cash Flow to Sales Ratio | -0.08 | -0.18 | -0.18 | -0.22 | -0.18 |
| Free Cash Flow Yield | -19.02% | -10.55% | -5.93% | -3.58% | -1.97% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.63 | -8.27 | -15.67 | -29.68 | -49.14 |
| Price-to-Sales (P/S) Ratio | 0.73 | 2.21 | 4.15 | 8.96 | 10.70 |
| Price-to-Book (P/B) Ratio | 1.77 | 4.09 | 5.62 | 21.00 | 10.85 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.26 | -9.48 | -16.85 | -27.94 | -50.76 |
| Price-to-Operating Cash Flow Ratio | -9.71 | -12.43 | -22.44 | -41.46 | -58.74 |
| Price-to-Earnings Growth (PEG) Ratio | -0.79 | -0.74 | -3.02 | -0.29 | -0.14 |
| Enterprise Value Multiple | -3.67 | -12.37 | -21.36 | -36.38 | -59.05 |
| Enterprise Value | 158.28M | 520.42M | 833.19M | 1.32B | 933.47M |
| EV to EBITDA | -3.67 | -12.37 | -21.36 | -36.38 | -59.05 |
| EV to Sales | 0.74 | 2.49 | 4.45 | 9.31 | 9.89 |
| EV to Free Cash Flow | -5.37 | -10.67 | -18.10 | -29.02 | -46.91 |
| EV to Operating Cash Flow | -9.91 | -14.00 | -24.10 | -43.07 | -54.29 |
| Tangible Book Value Per Share | 1.07 | 1.48 | 1.91 | 1.10 | 1.72 |
| Shareholders’ Equity Per Share | 1.38 | 1.82 | 2.27 | 1.10 | 1.72 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 3.36 | 3.37 | 3.07 | 2.57 | 1.74 |
| Net Income Per Share | -0.93 | -0.90 | -0.81 | -0.77 | -0.38 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.10 | 1.10 | 1.12 | 1.11 | 1.25 |
| Research & Development to Revenue | 0.10 | 0.10 | 0.08 | 0.10 | 0.11 |
| SG&A to Revenue | 0.96 | 0.97 | 0.25 | 0.23 | 0.20 |
| Stock-Based Compensation to Revenue | 0.16 | 0.15 | 0.09 | 0.06 | 0.04 |
| Income Quality | 0.27 | 0.67 | 0.70 | 0.72 | 0.84 |
Currency in USD

